| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Tapentadol |
| Brand | Palexia® |
| Indication | For the management of adult patients with severe chronic/acute pain. |
| Assessment Process | |
| Rapid review commissioned | 19/10/2010 |
| Rapid review completed | 22/10/2020 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
| Full pharmacoeconomic assessment commissioned by HSE | 31/01/2011 |
| NCPE assessment completed | 08/04/2011 |
| NCPE assessment outcome | Reimbursement Recommended |
Tapentadol (Palexia®) may be considered cost-effective but should be reserved for patients who cannot tolerate existing strong oral opioids.